Publications by authors named "Rogier Dik"

Claim this Profile
C
Combined inactivation of MEK and mTOR can lead to synergistic cell death in glioblastoma models and associates with NF1-deficiency and a mesenchymal subtype.
Fleur M G Cornelissen, Yoran Broersma, Ravi S Narayan, Rogier Dik, Sander R Piersma

Mol Cancer Ther· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype.
Fleur M G Cornelissen, Yoran Broersma, Ravi S Narayan, Rogier Dik, Sander R Piersma

Mol Cancer Ther· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities.
Ravi S Narayan, Piet Molenaar, Jian Teng, Fleur M G Cornelissen, Irene Roelofs, Rogier Dik

Nat Commun· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of MEK162 as a Radiosensitizer for the Treatment of Glioblastoma.
Ravi S Narayan, Ana Gasol, Paul L G Slangen, Fleur M G Cornelissen, Tonny Lagerweij, Rogier Dik

Mol Cancer Ther· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures.
Ravi S Narayan, Carlos A Fedrigo, Eelke Brands, Rogier Dik, Lukas J A Stalpers

BMC Cancer· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis